- Home
- RIGL vs VREX Comparison
RIGL vs VREX Comparison
Compare RIGL & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- VREX
- Stock Information
- Founded
- RIGL 1996
- VREX 2016
- Country
- RIGL United States
- VREX United States
- Employees
- RIGL N/A
- VREX N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- VREX Industrial Machinery/Components
- Sector
- RIGL Health Care
- VREX Technology
- Exchange
- RIGL Nasdaq
- VREX Nasdaq
- Market Cap
- RIGL 335.5M
- VREX 443.9M
- IPO Year
- RIGL 2000
- VREX N/A
- Fundamental
- Price
- RIGL $38.85
- VREX $11.55
- Analyst Decision
- RIGL Buy
- VREX Strong Buy
- Analyst Count
- RIGL 5
- VREX 2
- Target Price
- RIGL $38.20
- VREX $19.50
- AVG Volume (30 Days)
- RIGL 995.6K
- VREX 545.0K
- Earning Date
- RIGL 08-05-2025
- VREX 08-07-2025
- Dividend Yield
- RIGL N/A
- VREX N/A
- EPS Growth
- RIGL N/A
- VREX N/A
- EPS
- RIGL 5.43
- VREX N/A
- Revenue
- RIGL $267,921,000.00
- VREX $821,400,000.00
- Revenue This Year
- RIGL $59.93
- VREX $5.01
- Revenue Next Year
- RIGL N/A
- VREX $2.97
- P/E Ratio
- RIGL $7.15
- VREX N/A
- Revenue Growth
- RIGL 105.62
- VREX N/A
- 52 Week Low
- RIGL $12.66
- VREX $6.76
- 52 Week High
- RIGL $43.72
- VREX $16.93
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- VREX 76.25
- Support Level
- RIGL $39.00
- VREX $11.22
- Resistance Level
- RIGL $42.08
- VREX $11.51
- Average True Range (ATR)
- RIGL 2.32
- VREX 0.49
- MACD
- RIGL -0.37
- VREX 0.05
- Stochastic Oscillator
- RIGL 53.26
- VREX 82.53
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About VREX Varex Imaging Corporation
Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.